These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Zohydro approval by food and drug administration: controversial or frightening? Manchikanti L; Atluri S; Candido KD; Boswell MV; Simopoulos TT; Grider JS; Falco FJ; Hirsch JA Pain Physician; 2014; 17(4):E437-50. PubMed ID: 25054396 [TBL] [Abstract][Full Text] [Related]
23. Concern about the Expanding Prescription Drug Epidemic: A Survey of Licensed Prescribers and Dispensers. Wright RE; Reed N; Carnes N; Kooreman HE Pain Physician; 2016 Jan; 19(1):E197-208. PubMed ID: 26752487 [TBL] [Abstract][Full Text] [Related]
24. Strengthening and rationalizing pharmacovigilance in the EU: where is Europe heading to? A review of the new EU legislation on pharmacovigilance. Borg JJ; Aislaitner G; Pirozynski M; Mifsud S Drug Saf; 2011 Mar; 34(3):187-97. PubMed ID: 21332243 [TBL] [Abstract][Full Text] [Related]
25. Introduction of direct-to-consumer advertising of prescription drugs in Canada: an opinion survey on regulatory policy. Mintzes B; Barer M; Lexchin J; Bassett KL Res Social Adm Pharm; 2005 Jun; 1(2):310-30. PubMed ID: 17138480 [TBL] [Abstract][Full Text] [Related]
26. Unapproved prescription cough, cold, and allergy drug products: recent US Food and Drug Administration regulatory action on unapproved cough, cold, and allergy medications. Ostroff C; Lee CE; McMeekin J Chest; 2011 Aug; 140(2):295-300. PubMed ID: 21813527 [TBL] [Abstract][Full Text] [Related]
27. The patient experience of patient-centered communication with nurses in the hospital setting: a qualitative systematic review protocol. Newell S; Jordan Z JBI Database System Rev Implement Rep; 2015 Jan; 13(1):76-87. PubMed ID: 26447009 [TBL] [Abstract][Full Text] [Related]
28. An Industry Survey on Managing the Pharmacovigilance System Master File in a Global Environment: The Need for a Pragmatic Approach. Lavery C; Emmott J; Jeck-Thole S; Rouben P; Usher D; van der Spuij W; Woodward L Pharmaceut Med; 2022 Aug; 36(4):233-245. PubMed ID: 35723862 [TBL] [Abstract][Full Text] [Related]
30. Trouble Spots in Online Direct-to-Consumer Prescription Drug Promotion: A Content Analysis of FDA Warning Letters. Kim H Int J Health Policy Manag; 2015 Aug; 4(12):813-21. PubMed ID: 26673465 [TBL] [Abstract][Full Text] [Related]
31. The US Opioid Crisis: Current Federal and State Legal Issues. Soelberg CD; Brown RE; Du Vivier D; Meyer JE; Ramachandran BK Anesth Analg; 2017 Nov; 125(5):1675-1681. PubMed ID: 29049113 [TBL] [Abstract][Full Text] [Related]
32. From pharmacovigilance to pharmacoperformance. Peachey J Drug Saf; 2002; 25(6):399-405. PubMed ID: 12071776 [TBL] [Abstract][Full Text] [Related]
33. The Enigma of Pharmacovigilance of Patient Support Programs: A Survey of Marketing Authorization Holders in Europe. Portnoff JM; Lewis DJ Ther Innov Regul Sci; 2017 Jul; 51(4):486-493. PubMed ID: 30227052 [TBL] [Abstract][Full Text] [Related]
34. Drug quality in South Africa: perceptions of key players involved in medicines distribution. Patel A; Norris P; Gauld R; Rades T Int J Health Care Qual Assur; 2009; 22(5):547-60. PubMed ID: 19725374 [TBL] [Abstract][Full Text] [Related]
35. Pharmacovigilance risk mitigation plans: action in public health to promote the safe use of medication. Botelho SF; Reis AM Cien Saude Colet; 2015 Dec; 20(12):3897-905. PubMed ID: 26691813 [TBL] [Abstract][Full Text] [Related]
36. The US drug safety system: role of the pharmaceutical industry. Gibson BR; Suh R; Tilson H Pharmacoepidemiol Drug Saf; 2008 Feb; 17(2):110-4. PubMed ID: 17724741 [TBL] [Abstract][Full Text] [Related]
37. Digital Direct-to-Consumer Advertising: A Perfect Storm of Rapid Evolution and Stagnant Regulation Comment on "Trouble Spots in Online Direct-to-Consumer Prescription Drug Promotion: A Content Analysis of FDA Warning Letters". Mackey TK Int J Health Policy Manag; 2016 Feb; 5(4):271-4. PubMed ID: 27239871 [TBL] [Abstract][Full Text] [Related]